Business Context and Reporting Period
This Form 8-K is a current report filed by Calyxt, Inc. (Note: The request metadata lists "Cibus, Inc.", but the filing text identifies the registrant as Calyxt, Inc.) on March 28, 2022, regarding events occurring on March 24, 2022. The filing addresses the approval of a new Performance Stock Unit (PSU) agreement and the grant of equity awards to certain executive officers under the Calyxt, Inc. 2017 Omnibus Incentive Plan.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on executive compensation and equity plan administration.
Material Changes and Equity Grants
On March 24, 2022, the Company granted equity awards to three executive officers. The specific grants are as follows:
- Michael Carr (President and CEO): 490,000 stock options, 163,000 One-Year RSUs, 205,000 Three-Year RSUs, and 205,000 PSUs.
- William Koschak (CFO): 250,000 stock options, 119,700 One-Year RSUs, 100,000 Three-Year RSUs, and 100,000 PSUs.
- Dr. Travis Frey (CTO): 250,000 stock options, 105,650 One-Year RSUs, 100,000 Three-Year RSUs, and 100,000 PSUs.
Vesting Terms:
- Stock Options: Ten-year term; vesting in one-fourth installments annually over four years.
- One-Year RSUs: Vest in full on January 1, 2023.
- Three-Year RSUs: Vest in one-third installments annually over three years.
- PSUs: Three-year performance period (2022-2024); vesting based on Board-approved objectives. Truncation applies in the event of a change in control.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors beyond standard compensation plan terms. The PSU Agreement is incorporated by reference as Exhibit 10.1.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2017 Omnibus Incentive Plan to assess remaining availability for future grants.
- Review the specific performance objectives for the PSUs (2022-2024) as they are determined by the Board and not detailed in this summary.
- Confirm the fair value of the granted options and RSUs in the Company's most recent 10-K or 10-Q to estimate total compensation expense impact.
- Check for any subsequent filings regarding changes to the vesting schedule or performance metrics.